IMVT · Immunovant Inc

-

Please sign in to comment on IMVT

1 Comment

Admin

4 years ago

Immunovant, Inc is currently in a long term downtrend where the price is trading 62.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Immunovant, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 181.3% to $-32M since the same quarter in the previous year.

Finally, its free cash flow grew by 23.3% to $-23M since the same quarter in the previous year.

Based on the above factors, Immunovant, Inc gets an overall score of 2/5.

ISIN	US45258J1025
Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology

Market Cap	2B
PE Ratio	None
Target Price	45.1539
Beta	0.81
Dividend Yield	None

ABOUT

Immunovant Inc

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT · Immunovant Inc

-

Immunovant Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Immunovant Inc using a moving average strategy